BEHIND THE NEWS: Zyprexa staggers, spurring worries over Eli Lilly’s future
Sure, Eli Lilly and Co. has a promising portfolio of new drugs and other potential blockbusters in the pipeline. But every time the Indianapolis drugmaker reports profits, Wall Street analysts spend much of their time slicing and dicing one number: Zyprexa sales. Their greatest fear: The schizophrenia medication will stop pulling its weight before other drugs pick up the slack, sapping sales and profits and further depressing the company’s already deflated stock. Indeed, the stakes are huge. Zyprexa sales in…